Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions

In this article we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.

Recent Content

Researchers have detected circulating tumor cells in patients with glioblastoma multiforme (GBM), an aggressive type of brain malignancy.

Researchers have identified a gene signature that could be used to predict whether an estrogen receptor- positive (ER-positive) breast cancer patient will respond to the hormone therapy tamoxifen.

The anti-programmed-death-receptor-1 (PD-1) antibody, pembrolizumab (MK-3475), is effective and tolerable in patients with metastatic melanoma who have previously received another metastatic melanoma therapy.

A 34-year-old man presents with a soft tissue induration in the right thigh. A biopsy of the mass is performed. What is your diagnosis?

The conversation was about metaphors for coping with cancer:

A personalized immunotherapy called chimeric antigen receptor (CAR) therapy has been given the "breakthrough therapy" designation by the U.S. Food and Drug Administration (FDA).

The use of bevacizumab or cetuximab, in combination with either the FOLFOX  (leucovorin/5-fluorouracil/ oxaliplatin) or FOLFIRI (leucovorin/5-fluoruracil/irinotecan) chemotherapy regimen, achieved similarly effective overall survival (OS)

By clicking Accept, you agree to become a member of the UBM Medica Community.